Bausch + Lomb Corp (BLCO)$15.92
Market Cap: 4.02 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Bausch + Lomb Corp (BLCO).
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
DCF ready
Valuation
-131.6x
EV/FCF, N/A FCF yield
Quality
-3.1%
ROIC, -1.3% FCF margin
Growth
8.4%
5Y sales (revenue) CAGR
Balance sheet
0.8x
Debt/equity, 1.6x current ratio
Superinvestors
2
Top: Howard Marks (1.3%)
Strengths to research
- Revenue compounded at 8.4% over five years.
- Debt/equity looks manageable at 0.8x.
Watchouts
- Free cash flow margin is negative at -1.3%.
Annual data: 6 periods
Quarterly data: 20 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for BLCO.
Grade F
20
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| BLCO Target | Bausch + Lomb Corp | $4.0B | -15.6x | -131.6x | -3.1% | 8.4% | -1.3% | N/A | 16.9x | N/A |
| TFX | TELEFLEX INCORPORATED | $5.5B | -6.6x | 5362.4x | -15.7% | -4.7% | 0.1% | 56.2% | 13.0x | N/A |
| NVST | Envista Holdings Corp. | $2.9B | 83.7x | 13.5x | 1.0% | 7.1% | 8.5% | 54.7% | 0.7x | N/A |
| RGEN | Repligen Corp. | $7.9B | 133.8x | 84.1x | 1.8% | N/A | N/A | N/A | -0.3x | N/A |
| AVTR | Avantor arinc. | $8.6B | -10.4x | 24.6x | -5.6% | 0.5% | 7.6% | 32.7% | N/A | N/A |
| SOLV | Solventum Corp | $11.6B | 8.7x | -1572.9x | 15.4% | N/A | -0.1% | 53.5% | 1.6x | N/A |
| HOLX | Hologic Inc. | $11.8B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| ALGN | Align Technology Inc. | $13.0B | 29.0x | 24.3x | 10.1% | 10.3% | 12.2% | 67.2% | -1.4x | N/A |
| BAX | Baxter International Inc. | $15.6B | -10.3x | 69.5x | -6.1% | -0.7% | 3.0% | 30.1% | 11.1x | N/A |
Financial Charts
No financial data available for BLCO (annual).
2 superinvestors own BLCO
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Carl Icahn Icahn Capital Management | 3,500,000 | $56M | 0.65% | 0.0% |
| Howard Marks Oaktree Capital Management | 3,382,739 | $54M | 1.25% | 0.0% |